GlassScriptPhysician profile
Rajeev Rajendra
NPI 1992902803
$6,541.66
in general payments reported to CMS, 2019-2025
53 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,218 · 2020: $408 · 2021: $55.23 · 2022: $14.33 · 2023: $420 · 2024: $2,339 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,666 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,665.99 |
| Education | $179.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $758.89 | 2019-2025 | Erleada, Akeega, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $559.54 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $534.73 | 2019-2025 | |
| Pfizer INC. | $399.41 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $357.85 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Astellas Pharma US INC | $335.18 | 2019-2025 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $306.81 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $229.10 | 2019-2025 | Alecensa, Tecentriq, Rozlytrek |
| Jazz Pharmaceuticals INC. | $225.92 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $217.49 | 2023-2025 | Ninlaro, Fruzaqla, Iclusig |
| Abbvie INC. | $186.03 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $156.94 | 2023-2025 | Orgovyx |
| Tempus Ai, INC | $142.28 | 2024-2025 | Xt Cdx |
| Genzyme Corporation | $140.68 | 2019-2024 | |
| Cti Biopharma Corp. | $130.00 | 2023 | Vonjo |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Rajendra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.